Celgene Corp. (CELG)

82.41
NASDAQ : Health Technology
Prev Close 82.95
Day Low/High 82.20 / 84.17
52 Wk Low/High 74.13 / 137.45
Avg Volume 4.55M
Exchange NASDAQ
Shares Outstanding 703.36M
Market Cap 58.34B
EPS 3.80
P/E Ratio 19.25
Div & Yield N.A. (N.A)

Latest News

New Analyses From Pivotal Phase 3 Trials Of Oral Ozanimod To Be Presented At ECTRIMS 2018

New Analyses From Pivotal Phase 3 Trials Of Oral Ozanimod To Be Presented At ECTRIMS 2018

Celgene Corporation (NASDAQ:CELG) today announced the results of two post hoc analyses of data from the phase 3 SUNBEAM™ and RADIANCE™ Part B trials, which evaluated the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1...

Celgene Announces Phase 3 STYLE Study Of OTEZLA® (apremilast) In Moderate To Severe Scalp Psoriasis Met Primary Endpoint

Celgene Announces Phase 3 STYLE Study Of OTEZLA® (apremilast) In Moderate To Severe Scalp Psoriasis Met Primary Endpoint

Celgene Corporation (NASDAQ:CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA ® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician's...

Celgene Corporation To Announce Third Quarter 2018 Results On October 25, 2018

Celgene Corporation To Announce Third Quarter 2018 Results On October 25, 2018

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, October 25, 2018 at 9 a.

The Market Has Been Chopped Up for So Long That It Needs a Push

I don’t see anything but stocks going up a few bucks and then down a few bucks.

OTEZLA® (Apremilast) Showed Meaningful Improvements In Clinical And Quality-of-Life Measures Of Psoriasis Beyond Those Captured By Assessing Skin Alone

OTEZLA® (Apremilast) Showed Meaningful Improvements In Clinical And Quality-of-Life Measures Of Psoriasis Beyond Those Captured By Assessing Skin Alone

Celgene Corporation (NASDAQ:CELG) today announced the results of two post hoc sub-analyses of clinical trials for OTEZLA ® (apremilast) at the 27 th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.

Celgene Corporation To Webcast At Upcoming Investor Conferences

Celgene Corporation To Webcast At Upcoming Investor Conferences

Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company.

This Market Isn't Weak, It's Just Tired

The market needs a pullback.

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Celgene Reports Second Quarter 2018 Operating And Financial Results

Celgene Reports Second Quarter 2018 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $3,808 million for the second quarter of 2018, a 17 percent increase from the same period in 2017.

Celgene Announces Phase III 'AUGMENT' Study Of REVLIMID® In Combination With Rituximab (R2) For The Treatment Of Patients With Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint

Celgene Announces Phase III 'AUGMENT' Study Of REVLIMID® In Combination With Rituximab (R2) For The Treatment Of Patients With Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint

Celgene Corporation (NASDAQ: CELG) today announced results from a phase III, randomized, double-blind, international clinical study (AUGMENT).

Morgan Stanley M&A Prowess to Remain Strong; Google Dealt Another EU Fine--ICYMI

Morgan Stanley M&A Prowess to Remain Strong; Google Dealt Another EU Fine--ICYMI

Here's what you need to know now for Wednesday, July 18.

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Some beaten up biotech names are finally coming back to life. Here's a look at the technical analysis.

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Investors have never gone wrong buying Netflix on the dips. Jim Cramer tells you what to make of the 'FANG Musketeers.'

Dow, S&P 500 Gain For Fourth Day; Nasdaq Ends Flat

Dow, S&P 500 Gain For Fourth Day; Nasdaq Ends Flat

The Dow and S&P 500 booked a fourth straight day of gains Tuesday, while the Nasdaq ended flat as earnings season got underway.

Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced The Risk Of Disease Worsening Or Death In Patients With Metastatic Or Locally Advanced Triple Negative Breast Cancer In Phase III IMpassion130 Study

Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced The Risk Of Disease Worsening Or Death In Patients With Metastatic Or Locally Advanced Triple Negative Breast Cancer In Phase III IMpassion130 Study

Celgene Corporation (NASDAQ:CELG) today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS).

These Stocks Are Still Bargains: Cramer's 'Mad Money' Recap (Monday 7/9/18)

These Stocks Are Still Bargains: Cramer's 'Mad Money' Recap (Monday 7/9/18)

Even after Monday's rally, these stocks are terrific, says Jim Cramer. Here's how to play the great employment numbers.

Celgene And Acceleron Announce Luspatercept Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study In Adults With Transfusion-Dependent Beta-Thalassemia

Celgene And Acceleron Announce Luspatercept Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study In Adults With Transfusion-Dependent Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE).

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Celgene Is Turning Up as Bulls Gain Control

Celgene Is Turning Up as Bulls Gain Control

With biotech names getting some attention this morning a quick review looks like a good idea.

Celgene Corporation To Announce Second Quarter 2018 Results On July 26, 2018

Celgene Corporation To Announce Second Quarter 2018 Results On July 26, 2018

Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, July 26, 2018 at 9 a.

Celgene And Acceleron Announce Luspatercept Achieved Primary And Key Secondary Endpoints In Phase III 'MEDALIST' Study In Patients With Low-to-Intermediate Risk Myelodysplastic Syndromes

Celgene And Acceleron Announce Luspatercept Achieved Primary And Key Secondary Endpoints In Phase III 'MEDALIST' Study In Patients With Low-to-Intermediate Risk Myelodysplastic Syndromes

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST).

Celgene Price Weakness in Rear-View Mirror

Celgene Price Weakness in Rear-View Mirror

Charts suggest Celgene has put in a low for now.

Celgene Corporation Announces Appointment Of Jonathan Biller As Executive Vice President And General Counsel Following The Departure Of Gerald F. Masoudi

Celgene Corporation Announces Appointment Of Jonathan Biller As Executive Vice President And General Counsel Following The Departure Of Gerald F. Masoudi

Celgene Corporation (NASDAQ:CELG) today announced the appointment of Jonathan Biller as Executive Vice President and General Counsel effective July 3, 2018.

12 Stocks That Make Up the GLUM Index

12 Stocks That Make Up the GLUM Index

Here is a new index for all you traders out there to follow, compliments of TheStreet's founder Jim Cramer. Welcome to the GLUM Index.

Jim Cramer: A GLUM Index For Gloomy Markets

Jim Cramer: A GLUM Index For Gloomy Markets

Taking the measure of what's keeping the markets in the dumps.

Okta, Celgene, Altria: 'Mad Money' Lightning Round

Okta, Celgene, Altria: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Okta, Celgene, GasLog Partners, Neutral Tandem, Altria, Axovant Sciences, Lowe's and more.

TheStreet Quant Rating: C+ (Hold)